JP2012505162A

JP2012505162A - 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用

黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用 Download PDF

Info

Publication number: JP2012505162A
Authority: JP; Japan
Prior art keywords: scyllo; macular degeneration; subject; inositol; therapy
Prior art date: 2008-10-09
Legal status : Pending

Application number

JP2011530339A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012505162A5 (enExample

Inventor

アントニオクルツ，

Original Assignee

ワラタファーマシューティカルズ，インコーポレイテッド

Priority date

2008-10-09

Filing date

2009-10-09

Publication date

2012-03-01

2009-10-09 Application filed by ワラタファーマシューティカルズ，インコーポレイテッド filed Critical ワラタファーマシューティカルズ，インコーポレイテッド

2012-03-01 Publication of JP2012505162A publication Critical patent/JP2012505162A/ja

2012-11-22 Publication of JP2012505162A5 publication Critical patent/JP2012505162A5/ja

Status Pending legal-status Critical Current

Links

CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims abstract description 226
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 197
208000002780 macular degeneration Diseases 0.000 title claims abstract description 179
CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 title claims abstract description 63
-1 —PO 3 H 2 Chemical group 0.000 claims abstract description 249
238000000034 method Methods 0.000 claims abstract description 133
125000000217 alkyl group Chemical group 0.000 claims abstract description 37
208000024891 symptom Diseases 0.000 claims abstract description 37
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 23
125000001424 substituent group Chemical group 0.000 claims abstract description 14
125000003342 alkenyl group Chemical group 0.000 claims abstract description 13
125000000304 alkynyl group Chemical group 0.000 claims abstract description 11
230000007850 degeneration Effects 0.000 claims abstract description 11
229910052736 halogen Inorganic materials 0.000 claims abstract description 11
150000002367 halogens Chemical group 0.000 claims abstract description 11
208000035475 disorder Diseases 0.000 claims description 160
239000003814 drug Substances 0.000 claims description 111
238000011282 treatment Methods 0.000 claims description 102
238000002560 therapeutic procedure Methods 0.000 claims description 55
210000001508 eye Anatomy 0.000 claims description 47
206010064930 age-related macular degeneration Diseases 0.000 claims description 35
239000003963 antioxidant agent Substances 0.000 claims description 33
230000002137 anti-vascular effect Effects 0.000 claims description 31
239000000546 pharmaceutical excipient Substances 0.000 claims description 31
108010041308 Endothelial Growth Factors Proteins 0.000 claims description 30
239000003937 drug carrier Substances 0.000 claims description 30
239000003981 vehicle Substances 0.000 claims description 28
125000002252 acyl group Chemical group 0.000 claims description 25
238000002428 photodynamic therapy Methods 0.000 claims description 23
229910052739 hydrogen Inorganic materials 0.000 claims description 20
239000001257 hydrogen Substances 0.000 claims description 19
230000000649 photocoagulation Effects 0.000 claims description 19
230000003078 antioxidant effect Effects 0.000 claims description 15
241000282414 Homo sapiens Species 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 14
150000002431 hydrogen Chemical class 0.000 claims description 13
238000012014 optical coherence tomography Methods 0.000 claims description 12
239000000825 pharmaceutical preparation Substances 0.000 claims description 12
229940127557 pharmaceutical product Drugs 0.000 claims description 12
230000004044 response Effects 0.000 claims description 12
208000005590 Choroidal Neovascularization Diseases 0.000 claims description 11
206010060823 Choroidal neovascularisation Diseases 0.000 claims description 11
230000001965 increasing effect Effects 0.000 claims description 11
230000004393 visual impairment Effects 0.000 claims description 11
201000004569 Blindness Diseases 0.000 claims description 10
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical group COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 9
230000002411 adverse Effects 0.000 claims description 9
230000004438 eyesight Effects 0.000 claims description 9
239000012530 fluid Substances 0.000 claims description 9
229940076783 lucentis Drugs 0.000 claims description 9
230000002207 retinal effect Effects 0.000 claims description 9
208000000208 Wet Macular Degeneration Diseases 0.000 claims description 8
125000001153 fluoro group Chemical group F* 0.000 claims description 7
229940092110 macugen Drugs 0.000 claims description 7
125000000547 substituted alkyl group Chemical group 0.000 claims description 7
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
230000002491 angiogenic effect Effects 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
125000005415 substituted alkoxy group Chemical group 0.000 claims description 3
230000033115 angiogenesis Effects 0.000 claims description 2
230000000740 bleeding effect Effects 0.000 claims description 2
210000003161 choroid Anatomy 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 74
150000001875 compounds Chemical class 0.000 abstract description 46
125000003545 alkoxy group Chemical group 0.000 abstract description 15
239000008194 pharmaceutical composition Substances 0.000 abstract description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
235000002639 sodium chloride Nutrition 0.000 description 43
230000001225 therapeutic effect Effects 0.000 description 41
150000003839 salts Chemical class 0.000 description 38
230000000694 effects Effects 0.000 description 35
238000009472 formulation Methods 0.000 description 35
201000010099 disease Diseases 0.000 description 34
210000001519 tissue Anatomy 0.000 description 33
235000006708 antioxidants Nutrition 0.000 description 29
239000007924 injection Substances 0.000 description 29
238000002347 injection Methods 0.000 description 29
102000013455 Amyloid beta-Peptides Human genes 0.000 description 22
108010090849 Amyloid beta-Peptides Proteins 0.000 description 22
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
241001465754 Metazoa Species 0.000 description 18
150000003254 radicals Chemical class 0.000 description 18
229940079593 drug Drugs 0.000 description 17
229940124597 therapeutic agent Drugs 0.000 description 17
210000004027 cell Anatomy 0.000 description 16
239000000126 substance Substances 0.000 description 16
239000002904 solvent Substances 0.000 description 15
239000012453 solvate Substances 0.000 description 14
230000004304 visual acuity Effects 0.000 description 14
239000000651 prodrug Substances 0.000 description 13
229940002612 prodrug Drugs 0.000 description 13
230000009467 reduction Effects 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 12
235000005911 diet Nutrition 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
230000037213 diet Effects 0.000 description 11
230000002265 prevention Effects 0.000 description 11
230000000069 prophylactic effect Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
241000124008 Mammalia Species 0.000 description 10
235000012000 cholesterol Nutrition 0.000 description 10
238000002648 combination therapy Methods 0.000 description 10
238000005259 measurement Methods 0.000 description 10
239000008177 pharmaceutical agent Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
238000002405 diagnostic procedure Methods 0.000 description 9
230000006870 function Effects 0.000 description 9
239000007788 liquid Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
125000004423 acyloxy group Chemical group 0.000 description 8
230000006933 amyloid-beta aggregation Effects 0.000 description 8
230000037396 body weight Effects 0.000 description 8
239000002775 capsule Substances 0.000 description 8
238000011443 conventional therapy Methods 0.000 description 8
238000003745 diagnosis Methods 0.000 description 8
208000011325 dry age related macular degeneration Diseases 0.000 description 8
239000003889 eye drop Substances 0.000 description 8
239000007943 implant Substances 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
239000004480 active ingredient Substances 0.000 description 7
229940012356 eye drops Drugs 0.000 description 7
239000008187 granular material Substances 0.000 description 7
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
206010025421 Macule Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
239000000654 additive Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
235000015872 dietary supplement Nutrition 0.000 description 6
239000003651 drinking water Substances 0.000 description 6
235000020188 drinking water Nutrition 0.000 description 6
239000008103 glucose Substances 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
210000001525 retina Anatomy 0.000 description 6
239000013543 active substance Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
208000030533 eye disease Diseases 0.000 description 5
230000004410 intraocular pressure Effects 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
150000003573 thiols Chemical class 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 4
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 4
206010038848 Retinal detachment Diseases 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
125000003282 alkyl amino group Chemical group 0.000 description 4
238000002583 angiography Methods 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
235000019197 fats Nutrition 0.000 description 4
235000013305 food Nutrition 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
238000002372 labelling Methods 0.000 description 4
208000018769 loss of vision Diseases 0.000 description 4
231100000864 loss of vision Toxicity 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
235000021590 normal diet Nutrition 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
108091008695 photoreceptors Proteins 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
238000009736 wetting Methods 0.000 description 4
206010003694 Atrophy Diseases 0.000 description 3
230000007134 Aβ oligomerisation Effects 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
229930194542 Keto Natural products 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010047571 Visual impairment Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
208000038018 age-related macular disease Diseases 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
230000037444 atrophy Effects 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
125000004181 carboxyalkyl group Chemical group 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003086 colorant Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
230000012010 growth Effects 0.000 description 3
125000004438 haloalkoxy group Chemical group 0.000 description 3
208000000069 hyperpigmentation Diseases 0.000 description 3
230000003810 hyperpigmentation Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
125000000468 ketone group Chemical group 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
235000002949 phytic acid Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004264 retinal detachment Effects 0.000 description 3
239000000790 retinal pigment Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
125000004426 substituted alkynyl group Chemical group 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
239000013589 supplement Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
125000005309 thioalkoxy group Chemical group 0.000 description 3
125000005323 thioketone group Chemical group 0.000 description 3
238000012384 transportation and delivery Methods 0.000 description 3
208000029257 vision disease Diseases 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
101150037123 APOE gene Proteins 0.000 description 2
102100029470 Apolipoprotein E Human genes 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282836 Camelus dromedarius Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
206010010719 Conjunctival haemorrhage Diseases 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
206010015958 Eye pain Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
241000282819 Giraffa Species 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102100025136 Macrosialin Human genes 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000006550 Mydriasis Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000037111 Retinal Hemorrhage Diseases 0.000 description 2
201000007737 Retinal degeneration Diseases 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
208000027073 Stargardt disease Diseases 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102100030859 Tissue factor Human genes 0.000 description 2
JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000009471 action Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
108010081667 aflibercept Proteins 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000005236 alkanoylamino group Chemical group 0.000 description 2
125000005055 alkyl alkoxy group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000000427 antigen Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
208000010217 blepharitis Diseases 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 2
201000006754 cone-rod dystrophy Diseases 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000000151 deposition Methods 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000009510 drug design Methods 0.000 description 2
235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
229960005135 eicosapentaenoic acid Drugs 0.000 description 2
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
206010014801 endophthalmitis Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
125000004994 halo alkoxy alkyl group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
230000000642 iatrogenic effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
229960000367 inositol Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229940113601 irrigation solution Drugs 0.000 description 2
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
238000002430 laser surgery Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
235000012680 lutein Nutrition 0.000 description 2
229960005375 lutein Drugs 0.000 description 2
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
239000001656 lutein Substances 0.000 description 2
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
230000007483 microbial process Effects 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000002911 mydriatic effect Effects 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000001328 optic nerve Anatomy 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000000608 photoreceptor cell Anatomy 0.000 description 2
208000024335 physical disease Diseases 0.000 description 2
239000000467 phytic acid Substances 0.000 description 2
229940068041 phytic acid Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
229960003876 ranibizumab Drugs 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000004258 retinal degeneration Effects 0.000 description 2
210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
210000003583 retinal pigment epithelium Anatomy 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
208000026726 vitreous disease Diseases 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
235000010930 zeaxanthin Nutrition 0.000 description 2
239000001775 zeaxanthin Substances 0.000 description 2
229940043269 zeaxanthin Drugs 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
102100033639 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010054765 Anterior chamber inflammation Diseases 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241001416181 Axis axis Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283705 Capra hircus Species 0.000 description 1
206010007766 Cataract traumatic Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000002029 Claudin Human genes 0.000 description 1
108050009302 Claudin Proteins 0.000 description 1
102000003780 Clusterin Human genes 0.000 description 1
108090000197 Clusterin Proteins 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
206010010726 Conjunctival oedema Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
206010010984 Corneal abrasion Diseases 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
206010011033 Corneal oedema Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000283095 Elephas maximus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000009847 Eye Foreign Bodies Diseases 0.000 description 1
206010015946 Eye irritation Diseases 0.000 description 1
206010052140 Eye pruritus Diseases 0.000 description 1
206010057385 Eyelid irritation Diseases 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
208000008069 Geographic Atrophy Diseases 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100223244 Homo sapiens AMD1 gene Proteins 0.000 description 1
101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000887051 Homo sapiens Ubiquitin-like-conjugating enzyme ATG3 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283986 Lepus Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241000406668 Loxodonta cyclotis Species 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699696 Meriones Species 0.000 description 1
208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
DSCFFEYYQKSRSV-MVWKSXLKSA-N O-Methyl-scyllo-inositol Chemical compound COC1[C@@H](O)[C@H](O)C(O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-MVWKSXLKSA-N 0.000 description 1
206010052143 Ocular discomfort Diseases 0.000 description 1
241001420836 Ophthalmitis Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
201000010183 Papilledema Diseases 0.000 description 1
208000034247 Pattern dystrophy Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010034544 Periorbital haematoma Diseases 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
206010036346 Posterior capsule opacification Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000037048 Prodromal Symptoms Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102100024924 Protein kinase C alpha type Human genes 0.000 description 1
206010037508 Punctate keratitis Diseases 0.000 description 1
101150116978 RPE65 gene Proteins 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
108091006283 SLC17A7 Proteins 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000036038 Subretinal fibrosis Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
241000282894 Sus scrofa domesticus Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
102100039930 Ubiquitin-like-conjugating enzyme ATG3 Human genes 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
102000046052 Vesicular Glutamate Transport Protein 1 Human genes 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229960002833 aflibercept Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000000033 alkoxyamino group Chemical group 0.000 description 1
125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 description 1
125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003941 amyloidogenesis Effects 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
210000000467 autonomic pathway Anatomy 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000012730 carminic acid Nutrition 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229960005527 combretastatin A-4 phosphate Drugs 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000000205 computational method Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
201000001891 corneal deposit Diseases 0.000 description 1
201000004778 corneal edema Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000004300 dark adaptation Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000035614 depigmentation Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009429 distress Effects 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000002571 electroretinography Methods 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical class O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
KDKYADYSIPSCCQ-UHFFFAOYSA-N ethyl acetylene Natural products CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
231100000013 eye irritation Toxicity 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
239000000835 fiber Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
125000005980 hexynyl group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000004377 improving vision Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
229960004657 indocyanine green Drugs 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
150000004001 inositols Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229940063199 kenalog Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000003265 lymphadenitis Diseases 0.000 description 1
208000038015 macular disease Diseases 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
229960002525 mecamylamine Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004630 mental health Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical class O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
CDAISMWEOUEBRE-GNIYUCBRSA-N muco-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-GNIYUCBRSA-N 0.000 description 1
206010028093 mucopolysaccharidosis Diseases 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
201000005111 ocular hyperemia Diseases 0.000 description 1
230000008397 ocular pathology Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940100655 ophthalmic gel Drugs 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
208000010403 panophthalmitis Diseases 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960003407 pegaptanib Drugs 0.000 description 1
229940005014 pegaptanib sodium Drugs 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000005180 public health Effects 0.000 description 1
201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000004242 retinal defects Effects 0.000 description 1
201000011195 retinal edema Diseases 0.000 description 1
230000004243 retinal function Effects 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000002301 subretinal fluid Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
238000003325 tomography Methods 0.000 description 1
239000012929 tonicity agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
229960003895 verteporfin Drugs 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
229940061392 visudyne Drugs 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
208000000318 vitreous detachment Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
235000008210 xanthophylls Nutrition 0.000 description 1
150000003735 xanthophylls Chemical class 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1